|
Affiliation |
Faculty of Medicine School of Medicine Department of Internal Medicine, Hematology, Diabetes, and Endocrinology |
|
Title |
Assistant Professor |
|
External Link |
|
SHIDE Kotaro
|
|
|
Research Areas 【 display / non-display 】
-
Life Science / Hematology and medical oncology
Education 【 display / non-display 】
-
Kyushu University Graduate School, Division of Medical Sciences
- 2008.3
Country：Japan
-
Kyushu University Faculty of Medicine Department of Medicine
- 2001.3
Country：Japan
Professional Memberships 【 display / non-display 】
-
日本血液学会
2006.3
-
American Society of Hematology
2008.8
Papers 【 display / non-display 】
-
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis Reviewed International journal
Shide K., Takenaka K., Kitanaka A., Numata A., Kameda T., Yamauchi T., Inagaki A., Mizuno S., Takami A., Ito S., Hagihara M., Usuki K., Maekawa T., Sunami K., Ueda Y., Tsutsui M., Ando M., Komatsu N., Ozawa K., Kurokawa M., Arai S., Mitani K., Akashi K., Shimoda K.
Annals of Hematology 103 ( 1 ) 97 - 103 2024.1
Authorship：Lead author Language：English Publishing type：Research paper (scientific journal) Publisher：Annals of Hematology
There are few prospective studies on patients with post-essential thrombocythemia myelofibrosis (PET-MF) and post-polycythemia vera myelofibrosis (PPV-MF). Therefore, we conducted a nationwide longitudinal prospective survey to clarify the clinical characteristics of these diseases. A total of 197 PET-MF and 117 PPV-MF patients diagnosed between 2012 and 2021 were analyzed. The median age at diagnosis was 70.0 years for both diseases. The time from diagnosis of ET or PV to that of MF was 9.6 and 10.4 years, respectively, with no significant difference. Patients with PPV-MF had higher hemoglobin levels and white blood cell counts than those with PET-MF, whereas those with PET-MF had higher platelet counts than those with PPV-MF. Although splenomegaly was more frequent in patients with PPV-MF at diagnosis, there was no difference in the frequency of constitutional symptoms. Ruxolitinib was the most common treatment administered to 74.6% and 83.8% of patients with PET-MF and PPV-MF, respectively. Patients with PET-MF and PPV-MF had similar prognoses, with 3-year overall survival (OS) of 0.742 in PET-MF and 0.768 in PPV-MF patients. In both diseases, leukemic transformation was the leading cause of death, followed by infection. The 3-year OS for patients with PET/PPV-MF and primary MF diagnosed during the same period was 0.754 and 0.626, respectively, with no significant difference. This survey provides real-world clinical features and prognostic data on secondary myelofibrosis in the ruxolitinib era.
-
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model Reviewed International journal
Shide K., Takenaka K., Kitanaka A., Numata A., Kameda T., Yamauchi T., Inagaki A., Mizuno S., Takami A., Ito S., Hagihara M., Usuki K., Maekawa T., Sunami K., Ueda Y., Tsutsui M., Ando M., Komatsu N., Ozawa K., Kurokawa M., Arai S., Mitani K., Akashi K., Shimoda K.
Blood Cancer Journal 13 ( 110 ) 2023.7
Authorship：Lead author Publishing type：Research paper (scientific journal) Publisher：Blood Cancer Journal
DOI： 10.1038/s41408-023-00869-9
Other Link： https://www.nature.com/articles/s41408-023-00869-9
-
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma Reviewed International journal
Takuro Kameda, Kotaro Shide, Ayako Kamiunten, Yasunori Kogure, Daisuke Morishita, Junji Koya, Yuki Tahira, Keiichi Akizuki, Takako Yokomizo-Nakano, Sho Kubota, Kosuke Marutsuka, Masaaki Sekine, Tomonori Hidaka, Yoko Kubuki, Yuichi Kitai, Tadashi Matsuda, Akinori Yoda, Takayuki Ohshima, Midori Sugiyama, Goro Sashida, Keisuke Kataoka, Seishi Ogawa, Kazuya Shimoda
Commun Biol 5 ( 1 ) 1309 2022.11
Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Nature
DOI： 10.1038/s42003-022-04284-x.
DOI： 10.1038/s42003-022-04284-x.
Other Link： https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709164/
-
Calreticulin mutations in myeloproliferative neoplasms Invited Reviewed International journal
Kotaro Shide
International Review of Cell and Molecular Biology 2021.7
Authorship：Lead author, Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：Elsevier Inc.
-
Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice Reviewed International journal
Yoshinori Ozono, Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Yuki Tahira, Masaaki Sekine, Keiichi Akizuki, Kenichi Nakamura, Hisayoshi Iwakiri, Mitsue Sueta, Tomonori Hidaka, Yoko Kubuki, Shojiro Yamamoto, Satoru Hasuike, Akira Sawaguchi, Kenji Nagata & Kazuya Shimoda
Leukemia 35 ( 2 ) 454 - 467 2021.2
Language：English Publishing type：Research paper (scientific journal)
Books 【 display / non-display 】
-
「Topics MPN分子病態研究の進歩」EBM血液疾患の治療 2023-2024
幣 光太郎（ Role： Contributor , Ⅲ.白血病 E.骨髄増殖性腫瘍(MPN) Topics）
中外医学社 2022.10 （ ISBN:978-4-498-22540-4 ）
Total pages：572 Responsible for pages：235-236 Language：Japanese Book type：Scholarly book
-
Polycythemia vera, essential thrombocythemia, primary myelofibrosis. TODAY'S THERAPY 2021
（ Role： Contributor）
2021.1
Total pages：5 Responsible for pages：708-712 Language：Japanese Book type：Scholarly book
-
「多血症の鑑別診断」 ここが知りたい！血液疾患診療ハンドブック
幣 光太郎（ Role： Contributor , 第Ⅲ章 鑑別診断 2. 多血症の鑑別診断）
中外医学社 2022.10 （ ISBN:978-4-498-22538-1 ）
Total pages：304 Responsible for pages：85-93 Language：Japanese Book type：Scholarly book
-
QUESTION BANK 2023 血液
朝倉英策, 神田橋宏治, 後藤明彦, 幣光太郎, 玉井佳子, 中世古知昭, 森近一穂, 和田秀穂 他（ Role： Contributor , 骨髄系腫瘍）
メディックメディア 2022.3 （ ISBN:978-4-89632-862-2 ）
Language：Japanese Book type：Textbook, survey, introduction
-
「骨髄線維症」特発性造血障害疾患の診断の参照ガイド 令和元年度改訂版
赤司浩一、小松則夫、下田和哉、桐戸敬太、竹中克斗、幣光太郎、沼田晃彦（ Role： Contributor , 骨髄線維症 診療の参照ガイド令和１年改訂版（第５版））
厚生労働科学研究費補助金(難治性疾患政策研究事業) 特発性造血障害に関する調査研究班 2020.8
Total pages：34 Responsible for pages：231-264 Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
特集〈Clinical Science〉アンメットニーズに対するJAK阻害薬の可能性骨髄増殖性腫瘍に対するJAK阻害薬の治療効果 Invited
幣 光太郎 下田 和哉
炎症と免疫 32 ( 2 ) 29 - 32 2024.2
Authorship：Lead author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：先端医学社
-
The molecular pathogenesis of myelofibrosis and polycythemia vera, and the effect of JAK inhibitors. Invited
Rheumatology 70 ( 6 ) 608 - 614 2023.12
Authorship：Lead author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Advances in understanding the pathogenesis of myeloproliferative neoplasms. Invited
Hematology 86 ( 5 ) 745 - 749 2023.5
Authorship：Lead author, Corresponding author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
-
Positioning of JAK inhibitors in the initial treatment of myelofibrosis. Invited
Clinical oncology 31 ( 4 ) 432 - 437 2023.4
Authorship：Lead author, Corresponding author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
-
New aspects of myeloproliferative neoplasms: COVID-19 and myeloproliferative neoplasms Invited Reviewed
Kotaro Shide
Rinsho ketsueki 63 ( 6 ) 647 - 654 2022.7
Authorship：Lead author, Corresponding author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
Presentations 【 display / non-display 】
-
TYK2 Is Essential for IFNα-Induced Resolution of MPN Features in a Murine Jak2V617F PMF Model International conference
Yuki Tahira, Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Keiichi Akizuki, Masayoshi Karasawa, Ryoma Ikeda, Kengo Matsumoto, Yoko Kubuki, and Kazuya Shimoda
The 65th ASH Annual Meeting (San Diego, CA) 2023.12.11 米国血液学会
Event date： 2023.12.9 - 2023.12.12
Language：English Presentation type：Oral presentation (general)
Venue：San Diego, CA Country：United States
-
Significance of C-terminal amino acid sequence of CALR mutant proteins in inducing MPNs
The 85th Annual Meeting of the Japanese Society of Hematology (Tokyo) 2023.10.14 The Japanese Society of Hematology
Event date： 2023.10.13 - 2023.10.15
Language：Japanese Presentation type：Oral presentation (general)
Venue：Tokyo Country：Japan
-
COVID-19-associated thrombosis in cancer Invited
The 45th Congress of the Japanese Society on Thrombosis and Homeostasis 2023.6.15 The Japanese Society on Thrombosis and Homeostasis
Event date： 2023.6.15 - 2023.6.17
Language：English Presentation type：Symposium, workshop panel (nominated)
-
Role of driver mutations revealed from MPN mouse models.(Asian Session 2 : MPN study in Asia) Invited International conference
Kotaro Shide
The 12th JSH International Symposium 2021 in Kamaura (Kamakura) 2021.5.14 Japanese society of Hematology
Event date： 2021.5.14 - 2021.5.15
Language：English Presentation type：Oral presentation (general)
Venue：Kamakura Country：Japan
-
Depletion of Neoplastic CD11b Positive Cells in Jak2V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis International conference
Yoshinori Ozono, Kotaro Shide 他
American Society of Hematology the 61st Annual Meeting and Exposition (Orlando, FL, 米国) American Society of Hematology
Event date： 2019.12.7 - 2019.12.10
Language：English Presentation type：Oral presentation (general)
Venue：Orlando, FL, 米国
Awards 【 display / non-display 】
-
公益信託日本白血病研究基金一般研究賞
2017.11 公益信託日本白血病研究基金 骨髄増殖性腫瘍の発症・進展における、calreticulin機能不全の分子機構解明と治療法への展開
幣 光太郎
Award type：Award from publisher, newspaper, foundation, etc. Country：Japan
-
平成25年度日本血液学会奨励賞
2013.10 日本血液学会
幣 光太郎 宮崎大学 内科学講座 消化器血液学分野
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
炎症と血栓形成の新仮説に基づく骨髄増殖性腫瘍の病態制御
Grant number：23K07817 2023.04 - 2026.03
日本学術振興会 科学研究費助成事業 基盤研究(C)
Authorship：Principal investigator
-
腫瘍性fibrocyteの本態解明と、骨髄線維症診断・治療への展開
Grant number：23H02938 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究（B）
下田 和哉
Authorship：Coinvestigator(s)
-
CALR変異幹細胞の増幅機構及び変異体の機能モチーフを標的とした骨髄線維症の制御
Grant number：19K08819 2019.04 - 2022.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
-
CALRが関わる造血シグナル伝達と、その破綻による骨髄増殖性腫瘍発症機序の解明
2016.04 - 2019.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
-
骨髄線維症における難治性病態の分子メカニズム解明とその克服
2014.04 - 2016.03
科学研究費補助金 若手研究(B)
Authorship：Principal investigator
骨髄線維症における難治性病態の分子メカニズム解明とその克服